Tomulić Brusich, K., Juričić, K., Bobinac, M., Milošević, M., Protić, A. & Boban, A. (2023). Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome. Annals of Hematology, 102. (9), 2633-2634. doi: 10.1007/s00277-023-05335-x
Tomulić Brusich, Katarina, et al. "Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome." Annals of Hematology, vol. 102, no. 9, 2023, pp. 2633-2634. https://doi.org/10.1007/s00277-023-05335-x
Tomulić Brusich, Katarina, Kazimir Juričić, Mirna Bobinac, Marko Milošević, Alen Protić and Ana Boban. "Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome." Annals of Hematology 102, no. 9 (2023): 2633-2634. https://doi.org/10.1007/s00277-023-05335-x
Tomulić Brusich, K., et al. (2023) 'Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome', Annals of Hematology, 102(9), pp. 2633-2634. doi: 10.1007/s00277-023-05335-x
Tomulić Brusich K, Juričić K, Bobinac M, Milošević M, Protić A, Boban A. Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome. Annals of Hematology [Internet]. 2023 June 26 [cited 2024 August 21];102(9):2633-2634. doi: 10.1007/s00277-023-05335-x
K. Tomulić Brusich, K. Juričić, M. Bobinac, M. Milošević, A. Protić and A. Boban, "Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome", Annals of Hematology, vol. 102, no. 9, pp. 2633-2634, June 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:497704. [Accessed: 21 August 2024]